1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Memantine ER / Donepezil |
| brand | String | Namzaric |
| structure | File | |
| classes | List of String, delimiter: , | Combined cholinesterase inhibitor + NMDA antagonist |
| mechanism | String | Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. |
| uses | String | '"`UNIQ--vote-00000468-QINU`"' |
| starting_dose | String | For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength |
| preparations | String | 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) |
| fda_max | String | 28/10 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral (capsule whole or opened/sprinkled on applesauce) |
| onset | String | Component effects accumulate over weeks |
| duration | String | 24 h |
| halflife | String | ~60–80 h (memantine); ~70 h (donepezil) |
| bioavailability | String | ~100% both components |
| pregnancy | String | Not relevant (geriatric problem) |
| legal | String | Rx-only in US |
